Abstract
FLASH radiotherapy (FLASH-RT), characterized by ultra-high dose rates (>40 Gy/s), has demonstrated remarkable normal tissue-sparing effects in preclinical models while maintaining tumor control. This review specifically focuses on FLASH-mediated pulmonary protection, a critical concern in thoracic oncology. We critically evaluate proposed mechanisms—including oxygen depletion, radical recombination, mitochondrial preservation, DNA integrity maintenance, metabolic modulation, and immune reprogramming—with an emphasis on the strength and limitations of current evidence across in vitro, in vivo, and emerging clinical studies. Additionally, we summarize recent technological advances enabling clinical translation, such as FLASH-compatible beam modalities, real-time dosimetry, and motion management strategies. Unlike previous reviews, we integrate these mechanisms into a unified conceptual model and provide a structured comparison of evidence quality and contradictions. This work aims to clarify current controversies, highlight knowledge gaps, and guide future research and clinical trial design for FLASH-RT-based lung protection.
Introduction
Radiotherapy is a cornerstone of cancer treatment, yet its efficacy is frequently constrained by the "collateral damage" inflicted upon healthy organs. In thoracic oncology, radiation-induced lung injury (RILI)—encompassing acute pneumonitis and chronic fibrosis—affects approximately 15–30% of patients. Conventional radiotherapy (CONV-RT) delivers doses at relatively low rates over several minutes. In contrast, FLASH radiotherapy (FLASH-RT) delivers the entire prescribed dose in less than a second, typically at rates exceeding 40 Gy/s. Preclinical evidence suggests that this ultra-high dose rate spares healthy lung tissue without compromising tumor control, a phenomenon known as the "FLASH effect."
Biological Mechanisms of the FLASH Effect
The biological basis for FLASH-mediated sparing is likely multifactorial, involving a complex interplay of physical, chemical, and biological processes.
Oxygen Depletion and Radical Recombination
One prominent hypothesis suggests that FLASH-RT consumes local oxygen so rapidly that it outpaces replenishment via diffusion. This creates a transient state of hypoxia in normal tissues, which are typically well-oxygenated (normoxic). Because hypoxic cells are more resistant to radiation damage, this provides a protective effect. Conversely, tumor cells are often already hypoxic and do not derive additional protection from this transient state. Furthermore, the instantaneous generation of a high concentration of free radicals may lead to "self-quenching," where radicals recombine with each other rather than damaging critical cellular components like DNA.
Cellular and Molecular Preservation
FLASH-RT appears to selectively protect the mitochondria—the cellular "powerhouses"—of normal cells. Studies indicate that FLASH induces fewer double-strand breaks in DNA and maintains better metabolic homeostasis compared to CONV-RT. Additionally, the rapid delivery of radiation may spare circulating immune cells (lymphocytes), as fewer of them pass through the radiation field during the sub-second exposure, thereby preserving the systemic anti-tumor immune response.
Technological Innovations and Challenges
Translating the FLASH effect from the laboratory to the clinic requires significant hardware and software innovation.
Beam Modalities
Early FLASH research primarily utilized electron beams, which have limited penetration depth. Recent advances have expanded the potential for FLASH-RT using proton beams (leveraging the Bragg peak for deep-seated tumors) and high-intensity photon beams. Each modality presents unique challenges in maintaining the required ultra-high dose rates across the entire treatment volume.
Dosimetry and Motion Management
Accurate dosimetry is a significant hurdle; standard radiation sensors often saturate or fail at the intensities required for FLASH. Real-time, millisecond-scale monitoring is essential for patient safety. Furthermore, the lung is a highly mobile organ. Delivering a sub-second burst of radiation requires precise synchronization with the respiratory cycle to ensure the beam accurately targets the tumor while avoiding critical structures like the heart.
Clinical Progress and Translational Bottlenecks
Clinical translation is underway, with early-phase trials such as FAST-01 and FAST-02 (targeting bone metastases) and the IMPULSE trial (melanoma) providing initial safety data. However, applying FLASH-RT to lung cancer remains challenging due to the complexity of human pulmonary biology compared to murine models. Future research must focus on standardized dosimetry protocols, advanced 4D-CT imaging for motion tracking, and larger-scale clinical trials to validate the lung-sparing effects in human patients.
Conclusion
FLASH-RT represents a potential paradigm shift in thoracic oncology, offering the possibility of increasing the therapeutic window by significantly reducing normal tissue toxicity. While the underlying mechanisms are still being elucidated, the integration of biological insights with technological breakthroughs in beam delivery and motion management will be key to realizing the clinical potential of FLASH-mediated pulmonary protection.
Summary updated